Recently, we retrospectively analyzed MLH1 rs1800734, MSH2 rs2303426, MSH3 rs26279, EXO1 rs1047840, and EXO1 rs9350 SNPs in HNSCC subjects that received concurrent chemoradiotherapy with CDDP/carboplatin as neoadjuvant, adjuvant or definitive treatment, and observed that patients with wild-type “GG” genotypes of MSH3 rs26279 and EXO1 rs1047840 presented shorter relapse-free survival (RFS) and overall survival (OS) compared to others; however, side effects and response to therapy were not evaluated in study [20]. Here, EXO1 is linked to head and neck squamous cell carcinoma.